1. Home
  2. ALT vs KURA Comparison

ALT vs KURA Comparison

Compare ALT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • KURA
  • Stock Information
  • Founded
  • ALT 1997
  • KURA 2014
  • Country
  • ALT United States
  • KURA United States
  • Employees
  • ALT N/A
  • KURA N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • KURA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ALT Health Care
  • KURA Health Care
  • Exchange
  • ALT Nasdaq
  • KURA Nasdaq
  • Market Cap
  • ALT 472.3M
  • KURA 492.9M
  • IPO Year
  • ALT N/A
  • KURA N/A
  • Fundamental
  • Price
  • ALT $5.40
  • KURA $5.69
  • Analyst Decision
  • ALT Strong Buy
  • KURA Strong Buy
  • Analyst Count
  • ALT 7
  • KURA 12
  • Target Price
  • ALT $21.00
  • KURA $24.50
  • AVG Volume (30 Days)
  • ALT 2.5M
  • KURA 1.2M
  • Earning Date
  • ALT 05-13-2025
  • KURA 05-01-2025
  • Dividend Yield
  • ALT N/A
  • KURA N/A
  • EPS Growth
  • ALT N/A
  • KURA N/A
  • EPS
  • ALT N/A
  • KURA N/A
  • Revenue
  • ALT $20,000.00
  • KURA $67,991,000.00
  • Revenue This Year
  • ALT $4,108.32
  • KURA $171.90
  • Revenue Next Year
  • ALT $3,900.06
  • KURA $60.51
  • P/E Ratio
  • ALT N/A
  • KURA N/A
  • Revenue Growth
  • ALT N/A
  • KURA N/A
  • 52 Week Low
  • ALT $3.55
  • KURA $5.41
  • 52 Week High
  • ALT $11.16
  • KURA $23.48
  • Technical
  • Relative Strength Index (RSI)
  • ALT 52.71
  • KURA 42.98
  • Support Level
  • ALT $5.38
  • KURA $5.56
  • Resistance Level
  • ALT $5.81
  • KURA $5.84
  • Average True Range (ATR)
  • ALT 0.35
  • KURA 0.34
  • MACD
  • ALT -0.03
  • KURA -0.02
  • Stochastic Oscillator
  • ALT 34.18
  • KURA 20.39

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Share on Social Networks: